Benefit-Risk Assessment for PD-1/PD-L1 Inhibitors in the Treatment of Non-Small Cell Lung Cancer

Li Zhuangqi, Yang Yue

Li Zhuangqi, Yang Yue

亚洲社会药学 . 2022, (3): 253 -259 .